NEUSTAR
3.7.2017 12:05:08 CEST | Business Wire | Press release
Neustar, Inc. (NYSE:NSR), a trusted, neutral provider of real-time information services, today announced that its ground-breaking DNS Shield(TM) solution has won the “Innovative Product of the Year” category at the 2017 Cyber Security Awards.
Rodney Joffe, Neustar SVP, Fellow, and DNS Shield creator said: "Our DNS Shield platform is designed to increase the resilience of our DNS infrastructure beyond the levels attainable by any other current technology. Under most circumstances, our DNS Shield nodes are impervious to disruption from DDoS attacks and global Internet disruptions that would cause other DNS systems to fail catastrophically. Growing the DNS Shield platform is a key component to our security architecture. We are already protecting over three hundred million consumers and businesses, spread across a number of major Service Provider Partners from DNS outages, and ensuring unparalleled DNS security and reliability for thousands of customers. We are delighted that the Cyber Security Awards' judges recognise the value of DNS Shield and the innovation behind its development."
DNS Shield reengineers the Internet by hardwiring private network connections between its authoritative servers and its partner’s recursive servers. The judges recognized this radically different industry-first approach in selecting Neustar as the award winner.
Now in their third year, the Cyber Security Awards are independent of any industry affiliations and open to all organizations that are committed to furthering the security industry. With the aim of rewarding the best individuals, teams, and companies within the cyber security industry, every category is judged on excellence and innovation. The judging panel includes senior executives, security professionals and academics from a range of organizations including, Credit Suisse, Aviva, Warwick University and Executive Risk Magazine.
The winners were announced at a glittering black-tie ceremony on June 29th at the Chelsea Harbour Hotel in central London.
About Neustar Security Solutions
Neustar Security Solutions defend against network threats, inform you of potential network vulnerabilities, accelerate online asset performance, and monitor client website performance through multiple services and offerings. Neustar will offer the largest, most distributed DDoS mitigation network in the world with over 10 Tbps of capacity, and our industry leading SiteProtect DDoS protection service ensures full coverage in an attack. Our UltraDNS service manages 10 percent of all internet traffic, routes over 1T queries a month and provides industry leading uptime and 100 percent website availability. Neustar’s IP Intelligence is the authoritative source of IP decisioning data on 99.9 percent of routable IP addresses worldwide. Our 19+ years of unparalleled expertise ensures that our customers are protected and optimized during normal business practices and when unsolicited events occur. Our services ensure customers network connectivity are protected and optimized whether in crisis or just business as usual. We are trusted by many of the world’s largest brands to keep their mission critical systems up and running.
About Neustar
Every day, the world generates roughly 2.5 quadrillion bits of data. Neustar (NYSE:NSR) isolates certain elements and analyzes, simplifies and edits them to make precise and valuable decisions that drive results. As one of the few companies capable of knowing with certainty who is on the other end of every interaction, we’re trusted by the world’s great brands to make critical decisions some 20 billion times a day. We help marketers send timely and relevant messages to the right people. Because we can authoritatively tell a client exactly who is calling or connecting with them, we make critical realtime responses possible. And the same comprehensive information that enables our clients to direct and manage orders also stops attackers. We know when someone isn’t who they claim to be, which helps stop fraud and denial of service before they’re a problem. Because we’re also an experienced manager of some of the world’s most complex databases, we help clients control their online identity, registering and protecting their domain name, and routing traffic to the correct network address. By linking the most essential information with the people who depend on it, we provide more than 11,000 clients worldwide with decisions—not just data. More information is available at https://www.neustar.biz
View source version on businesswire.com: http://www.businesswire.com/news/home/20170703005189/en/
Contact:
Neustar Media Contact
Laura Cahill
Laura.cahill@axicom.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
